Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for BioLineRx (BLRX) over the last 1 years, with Jun 2025 value amounting to -$12.5 million.

  • BioLineRx's Change in Acquisitions & Divestments was N/A to -$12.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$64.3 million, marking a year-over-year change of. This contributed to the annual value of -$26.4 million for FY2024, which is 44.63% up from last year.
  • According to the latest figures from Q2 2025, BioLineRx's Change in Acquisitions & Divestments is -$12.5 million, which was down 1.66% from -$12.3 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Change in Acquisitions & Divestments peaked at -$506,000 during Q2 2023, and registered a low of -$33.7 million during Q4 2023.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was -$7.9 million (2023), whereas its average is -$11.2 million.
  • Data for BioLineRx's Change in Acquisitions & Divestments shows a peak YoY increased of 26.47% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows BioLineRx's Change in Acquisitions & Divestments stood at -$33.7 million in 2023, then climbed by 26.47% to -$5.8 million in 2024, then reached -$12.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at -$12.5 million for Q2 2025, versus -$12.3 million for Q1 2025 and -$5.8 million for Q3 2024.